OSOBENNOSTI TERAPII PERVIChNOGO OSTEOARTROZA U PATsIENTOV S KOMORBIDNYMI ZABOLEVANIYaMI


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The article presents a comparative analysis of the efficacy and tolerability of parenteral form of chondroitin sulfate, and the combined symptom-modifying drug for oral administration (chondroitin sulfate + glucosamine sulfate) in the treatment of primary osteoarthritis in older patients with comorbid diseases. According to the results of the study, pronounced analgesic effect of Chondrogard with a minimum of adverse events was revealed, that can improve the safety of treatment of osteoarthrosis and reduce the risk of drug interactions in patients older than 55 years with comorbidity.

Texto integral

Acesso é fechado

Sobre autores

M. Udovika

Email: mayaud@rambler.ru

Bibliografia

  1. Зонова Е.В. Глюкозамин и хондроитина сульфат в терапии остеоартроза. Эффективная фармакотерапия. Ревматология, травматология и ортопедия. 2013; 52(2):36-42.
  2. Зонова Е.В. Остеоартроз. Выбор безопасной тактики лечения пациента с коморбидностью. Эффективная фармакотерапия. 2014;56(3):18-21.
  3. Roberts E.R., Green D., Kadam U.T. Chronic condition comorbidity and multidrug therapy in general practice populations: a cross-sectional linkage study. BMJ Open. 2014;7:e005429.
  4. National Collaborating Centr for Vental Health. Depression the NICE guideline on the treatment and management of depression in adults. London: British Psychological Society and Royal College of Psychiatrists. 2010.
  5. Tubach F., Ravaud P., Martin-Mola E., Awada H., Bellamy N., Bombardier C., Felson D.T., Hajjaj-Hassouni N., Hochberg M., Logeart I., Matucci-Cerinic M., van de Laar M., van der Heijde D., Dougados M. Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study. Arthritis Care Res. (Hoboken). 2012;64(11):1699-707.
  6. Алексеева Л.И. Современное лечение остеоартроза. Фарматека. Специальный выпуск: Остеопороз 2012;s1-12:22-27.
  7. Zhang W., Moskowitz R. W., Nuki G. Abramson S., Altman R.D., Arden N., Bierma-Zeinstra S., Brandt K.D., Croft P., Doherty M., Dougados M., Hochberg M., Hunter D.J., Kwoh K., Lohmander L.S., Tugwell P. OARSI recommendations for the management of hip and knee osteoarthrosis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthrosis Cartilage. 2008;16:137-162.
  8. Zhang W., Nuki G., Moskowitz R. W. Abramson S., Altman R.D., Arden N.K., Bierma-Zeinstra S., Brandt K.D., Croft P., Doherty M., Dougados M., Hochberg M., Hunter D.J., Kwoh K., Lohmander L.S., Tugwell P. OARSI recommendations for the management of hip and knee Osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010;18:476-99.
  9. Volpi N. Chondroitin sulphate for the treatment of osteoarthritis - Anti-Inflammatory and Anti-Allergy Agents. Curr. Med. Chem. 2005; 4:221-34.
  10. Kellgren J.H., Lawrence J.S. Radiografhic assessment of osteoarthritis. Ann. Rheum. Dis. 1957;16(4):494-501.
  11. Егорова Е.А. Возможности рентгеновских методик в оценке изменений тазобедренных суставов до и после эндопротезирования. Радиология - практика. 2012;2:4-17.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Bionika Media, 2015

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies